



PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  November 14, 2003  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-010		DIVISIONAL APPLICATION NO. 09/553,496	
	APPLICANT Sudhir V. Shah			
	FILING DATE	CONFIRMATION NO.	GROUP 1654	

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
W	AA	5,047,421	Sep 10, 1991	Green
W	AB	5,721,209	Feb 24, 1998	Horwitz <i>et al.</i>
W	AC	5,811,127	Sep 22, 1998	Milstein <i>et al.</i>
W	AD	4,684,482	Aug 4, 1987	Green
	AE			
	AF			
	AG			
	AH			
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER 	DATE CONSIDERED 04/26/04
---	-----------------------------


<b>PTO-1449 REPRODUCED</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>November 14, 2003</b>  (Use several sheets if necessary)	<b>ATTORNEY DOCKET NO.</b> 2629.1003-010		<b>DIVISIONAL APPLICATION NO.</b> 09/553,496	
	<b>APPLICANT</b> Sudhir V. Shah			
	<b>FILING DATE</b>		<b>CONFIRMATION NO.</b>	<b>GROUP</b> 1654

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
<i>N</i>	AL	WO 94/01770 A	20 Jan 94	PCT	X	
<i>L</i>	AM	DE 40 08 323 A	19 Sept 91	Germany	X	
<i>N</i>	AN	WO 00 13706 A	16 Mar 00	PCT (English)		
<i>N</i>	AO	WO 91 07956 A	13 June 91	PCT		
	AP					
	AQ					
	AL2					
	AM2					
	AN2					
	AO2					
	AP2					
	AQ2					
	AL3					
	AM3					
	AN3					
	AO3					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					
	AL5					
	AM5					

<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> 04/26/04
--	------------------------------------


PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  November 14, 2003  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-010		DIVISIONAL APPLICATION NO. 09/553,496	
	APPLICANT Sudhir V. Shah			
	FILING DATE		CONFIRMATION NO.	GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
W	AR	Sumboonnanda, A., <i>et al.</i> , "Renal tubular function in $\beta$ -thalassemia", <i>Pediatr Nephrol</i> , 12:280-283.
W	AS	Ong-ajyooth, L., <i>et al.</i> , "Renal Function in Adult Beta-Thalassemia/Hb E Disease", <i>Nephron</i> , 78:156-161 (1998).
N	AT	Guasch, A., <i>et al.</i> , "Evidence that Microdeletions in the $\alpha$ Globin Gene Protect Against the Development of Sick Cell Glomerulopathy in Humans", <i>J Am Soc Nephrol</i> , 10:1014-1019 (1999).
W	AU	Loebstein, R., <i>et al.</i> , "Diabetic Nephropathy in Hypertransfused Patients with $\beta$ -Thalassemia", <i>Diabetes Care</i> , 21(8):1306-1309 (1998).
N	AV	Ongajyooth, L., <i>et al.</i> , "Glomerulonephritis in $\beta$ -thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome", <i>J Med Assoc Thai</i> , 78(3):119-126 (1995).
N	AW	Aoki, R.Y., <i>et al.</i> , "Microalbuminuria in Sick Cell Disease", <i>Brazilian J Med Biol Res</i> , 23:1103-1106 (1990).
N	AX	Katopodis, K.P., <i>et al.</i> , "Renal Abnormalities in Patients with Sick Cell-Beta Thalassemia", <i>Journal of Nephrology</i> , 10(3):163-167 (1997).
N	AY	Pham, P.-T.T., <i>et al.</i> , "Renal abnormalities in sickle cell disease", <i>Kidney International</i> , 57:1-8 (2000).
N	AZ	Kontoghiorghes, G.J., <i>et al.</i> , "Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones", <i>Inorganica Chimica Acta.</i> , 136:L11-L12 (1987).
N	AR2	Falk, R.J., <i>et al.</i> , "Prevalence and Pathologic Features of Sick Cell Nephropathy and Response to Inhibition of Angiotensin-Converting Enzyme", <i>The New England Journal of Medicine</i> , 326(14):910-915 (1992).
N	AS2	Guasch, A., <i>et al.</i> , "Sickle cell anemia causes a distinct pattern of glomerular dysfunction", <i>Kidney International</i> , 51:826-833 (1997).
N	AT2	Cianciulli, P., <i>et al.</i> , "Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy", <i>Kidney International</i> , 46:467-470 (1994).
N	AU2	Ueda, N., <i>et al.</i> , "Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome", <i>Kidney International</i> , 49:370-373 (1996).

EXAMINER 	DATE CONSIDERED 04/26/04
---	-----------------------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  November 14, 2003  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2629.1003-010		DIVISIONAL APPLICATION NO. 09/553,496	
	APPLICANT Sudhir V. Shah			
	FILING DATE		CONFIRMATION NO.	GROUP 1654

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
N	AV2	Savill, J., <i>et al.</i> , "Mechanisms of glomerular injury". In "Oxford Textbook of Clinical Nephrology," 2 <sup>nd</sup> ed., pages 404-439, eds., Davidson, A.M., <i>et al.</i> , Oxford Univ. Press (1998).
N	AW2	Ueda, N., <i>et al.</i> , "In Vivo Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease", <i>Kidney: A Current Survey of World Literature</i> , 6:143-146 (1997).
N	AX2	Boyce, N.W., <i>et al.</i> , "Hydroxyl radical mediation of immune renal injury by desferrioxamine", <i>Kidney International</i> , 30:813-817 (1986).
P	AY2	Baliga, R., <i>et al.</i> , "Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet", <i>J Am Soc Nephrol</i> , 7(8):1183-1188 (1996).
N	AZ2	Shah, S.V., "Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats", <i>The American Physiological Society</i> , F337-F344(1988).
N	AR3	Thakur, V., <i>et al.</i> , "Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria", <i>Kidney International</i> , 34:494-499 (1988).
N	AS3	Nankivell, B.J., <i>et al.</i> , "The Role of Tubular Iron Accumulation in the Remnant Kidney", <i>J Am Soc Nephrol</i> , 4(8):1598-1607 (1994).
N	AT3	Alfrey, A.C., <i>et al.</i> , "Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis", <i>Kidney International</i> , 36:753-759 (1989).
N	AU3	El Nahas, A.M., "Mechanisms of experimental and clinical renal scarring" In: "Oxford Textbook of Clinical Nephrology", 2 <sup>nd</sup> ed., pages 1749-1788, eds., Davidson, A.M., <i>et al.</i> , Oxford Univ. Press (1998).
N	AV3	Howard R.L., <i>et al.</i> , "Urinary albumin, transferrin and iron excretion in diabetic patients", <i>International Society of Nephrology</i> , 40:923-926 (1991).
N	AW3	Olivieri, N.F., <i>et al.</i> , "Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major", <i>The New England Journal of Medicine</i> , 918-922 (1995).
N	AX3	Alfrey A.C., "Toxicity of tubule fluid iron in the nephrotic syndrome", <i>American Journal of Physiology</i> , 263(4):F637-F641 (1992).
N	AY3	Wu, Z-L., <i>et al.</i> , "Iron Loading Enhances Susceptibility to Renal Ischemia in Rats," <i>Renal Failure</i> 16(4):471-480 (1994).

EXAMINER 	DATE CONSIDERED 04/24/04
---	-----------------------------

[illegible]

@PFDesktop\:\ODMA\MHODMA\HBSR05; iManage:433983; 1